Results 91 to 100 of about 4,863 (192)
Tumor-stroma interactions influence the response to PI3K targeted agents in preclinical models of colorectal cancer (CRC) [PDF]
, 2019 Introduction: One of the main obstacle to the successful development of therapeutic strategies remains the identification of biomarker underlying drug resistance. Recently, investigators have become more aware the role of the tumor microenvironment (TME)
Bazzichetto, Chiara
core
BMEMat, Volume 3, Issue 3, September 2025.This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan +12 more
wiley +1 more source
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Biologics: Targets & Therapy, 2016 Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently
Koff JL, Lonial S
doaj
Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate [PDF]
, 2018 Traditionally, bioanalytical laboratories do not report actual concentrations for samples with results below the LOQ (BLQ) in pharmacokinetic studies.
Atholl Johnston +27 more
core +1 more source
Cytokine release syndrome in solid tumors
Cancer, Volume 131, Issue 17, 1 September 2025.Abstract Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to ...
David Synnott +3 more
wiley +1 more source
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer [PDF]
, 2010 Background: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive ...
B Berns +41 more
core +2 more sources
The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study
Oral Diseases, Volume 31, Issue 8, Page 2641-2651, August 2025.ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah +4 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 7, Page 1262-1272, July 2025.ABSTRACT Target‐mediated drug disposition (TMDD) is often associated with high‐affinity binding to a target resulting in nonlinear pharmacokinetics. For large molecules, such as monoclonal antibodies, this can lead to increased clearance at sub‐saturating concentrations.
Ronny Straube
wiley +1 more source
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
, 2016 Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early detection of invading pathogens, in initiating early innate immune response and in orchestrating the adaptive immune response.
Ferguson, Laura L. +3 more
core +1 more source